Catherine Isted Acma
About Catherine Isted Acma
Catherine Isted Acma is the Chief Financial Officer at BenevolentAI, with extensive experience in the healthcare and financial sectors, including previous roles at ReNeuron Group Plc, Oxford Biomedica, and Peel Hunt.
Company
Catherine Isted currently holds the position of Chief Financial Officer at BenevolentAI. BenevolentAI is headquartered in London/Cambridge, focusing on utilizing artificial intelligence for scientific discovery and innovation. Catherine joined the company in September 2023.
Title
Catherine Isted serves as the Chief Financial Officer at BenevolentAI. Previously, she has held significant roles such as Chief Executive Officer and Chief Financial Officer at ReNeuron Group Plc.
Education and Expertise
Catherine Isted has a solid educational foundation with a Bachelor's Degree in Chemistry, achieving first-class honors from the University of Leicester. She also holds the Chartered Management Accountant designation from The Chartered Institute of Management Accountants. Her expertise includes equity capital markets and finance leadership in the Lifesciences industry.
Professional Background
Catherine Isted's career includes prominent roles such as Chief Executive Officer at ReNeuron Group Plc, where she worked from 2022 to 2023, and Chief Financial Officer at ReNeuron from 2021 to 2022. She also held positions at Oxford Biomedica as Head of Corporate Development & IR and finance roles at Peel Hunt and Nomura Code. Her career spans various sectors including healthcare equities and pharmaceutical analytics, with notable roles at Morgan Stanley and Merck & Co.
Key Achievements
Catherine Isted played a crucial role in aiding Oxford Biomedica to achieve a market capitalization of over £1.5 billion and secure a spot in the FTSE 250. She also holds a former #1 EXTEL ranking by institutional investors in biotech and has overseen multiple IPOs and follow-on fundraisings. Her strategic insights into the healthcare industry are influenced by her diverse career path, from bench scientist in medicinal chemistry at Merck to partner-level positions in financial institutions.